Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Yulia Volchek"'
Autor:
Rosa Ayala, Nieves Lopez, Adi Shacham Abulafia, Maan Alwan, Costas K. Yannakou, Indu Raman, Vincent Ribrag, Chun Yew Fong, Yulia Volchek, Massimiliano Bonifacio, Alessandra Tucci, Jean-Jacques Kiladjian, Jésus Marïa Hernandez Rivas, Blanca Xicoy, Haifa Kathrin Al-Ali, Jean-Christope Ianotto, Si Tuen Lee-Hoeflich, Sharmilla Das, Bin Wu, Palanikumar Ravindran, Qian Zhao, Guan Wang, Oriana Esposito, Yu Liu, Zariana Nikolova, Christopher Tehlirian, Shodeinde Coker, David Lavie
Publikováno v:
HemaSphere, Vol 7, p e4785165 (2023)
Externí odkaz:
https://doaj.org/article/5471365b11ed4d9dae2a907cb4fdd2ca
Autor:
Rosa Ayala, Nieves Lopez, Adi Shacham Abulafia, Maan Alwan, Costas K. Yannakou, Indu Raman, Vincent Ribrag, Chun Yew Fong, Yulia Volchek, Massimiliano Bonifacio, Alessandra Tucci, Jean-Jacques Kiladjian, Henry Chang, Sharmila Das, Bin Wu, Palanikumar Ravindran, Vivian Shan, Guan Wang, Oriana Esposito, Yu Liu, Zariana Nikolova, Christopher Tehlirian, Shodeinde Coker, David Lavie
Publikováno v:
Blood. 140:9665-9667
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::429bef2ca89270b3b1fbb6c759956abf
https://doi.org/10.1182/blood-2022-159476
https://doi.org/10.1182/blood-2022-159476
Autor:
G. Rechavi, Drorit Merkel, Avichai Shimoni, Chen Gefen, Jonathan Canaani, Yulia Volchek, Noga Shem-Tov, Arnon Nagler, Meital Nagar, Ronit Yerushalmi, Abraham Avigdor, Gabriel Heering, Ninette Amariglio
Publikováno v:
Oncotarget
A substantial segment of patients with acute myeloid leukemia (AML) will relapse following an initial response to induction therapy or will prove to be primary refractory. High-dose cytarabine and mitoxantrone (HiDAC/MITO) is an established salvage t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a29f53291d5d8306d781e9b4d88bc6e
https://doi.org/10.18632/oncotarget.27618
https://doi.org/10.18632/oncotarget.27618
Autor:
Pia Raanani, Adi Shacham-Abulafia, Yulia Volchek, Evgeni Chubar, Uri Rozovski, David Lavie, Liat Shargian, Anna Gourevitch, Roy Ratzon, Ron Ram, Ilana Helman
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 18:e295-e301
Background The strict recruitment criteria of patients for clinical trials often lead to reduced generalizability of the findings. We studied how ponatinib is used outside clinical trials in patients with chronic myeloid leukemia (CML). Patients and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::811c35a429698d727898980337f1f106
https://doi.org/10.1016/j.clml.2018.05.002
https://doi.org/10.1016/j.clml.2018.05.002
Autor:
Ronit Yerushalmi, Avichai Shimoni, Elena Ribakovsky, Yulia Volchek, Jonathan Canaani, Danielle Fredman, Noga Shem-Tov, Keren Shichrur, Abraham Avigdor, Arnon Nagler, Gabriel Heering
Publikováno v:
Blood. 136:28-29
Background Chemotherapy based approaches still constitute an essential feature in the treatment paradigm of adult acute lymphoblastic leukemia (ALL). The German Multicenter Study Group (GMALL) is a well-established and commonly used protocol for ALL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c4e14ae7cfa68c0ea4835fbbd10c171b
https://doi.org/10.1182/blood-2020-134771
https://doi.org/10.1182/blood-2020-134771
Autor:
Shiran Eldror, Ronit Yerushalmi, Arnon Nagler, Noga Shem-Tov, Avichai Shimoni, Nira Varda-Bloom, Atar Lev, Raz Somech, Ivetta Danylesko, Jacqueline Davidson, E. Rosenthal, Roni Shouval, Yulia Volchek
Publikováno v:
Oncotarget
// Nira Varda-Bloom 1, 2, * , Ivetta Danylesko 1, 2, * , Roni Shouval 1, 2, 3, 4 , Shiran Eldror 1, 2 , Atar Lev 1, 2, 5, 6 , Jacqueline Davidson 1, 2 , Esther Rosenthal 1, 2 , Yulia Volchek 1, 2 , Noga Shem-Tov 1, 2 , Ronit Yerushalmi 1, 2 , Avichai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1935a4003dc154975491f15b90f789d4
https://doi.org/10.18632/oncotarget.13439
https://doi.org/10.18632/oncotarget.13439
Autor:
Filomena Daraio, Francesca Crasto, Yulia Volchek, Arnon Nagler, Ninette Amariglio, Roberta Lorenzatti, Giuseppe Saglio, Maya Koren-Michowitz, Enrico Gottardi, Avichai Shimoni
Publikováno v:
Biology of Blood and Marrow Transplantation. 21:1852-1855
Real-time quantitative PCR (RT-qPCR) is commonly used for follow-up of chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors, but its current sensitivity does not allow detection of very low BCR-ABL levels. Therefore RT-qPCR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::225a878eda29f70486b86d98b663c3ed
https://doi.org/10.1016/j.bbmt.2015.06.018
https://doi.org/10.1016/j.bbmt.2015.06.018
Autor:
Avichai Shimoni, Raz Somech, Maya Koren-Michowitz, Noga Shem-Tov, Nira Varda-Bloom, Yulia Volchek, Ronit Yerushalmi, Arnon Nagler
Publikováno v:
Cancer. 121:863-871
BACKGROUND Allogeneic stem cell transplantation (SCT) remains the standard treatment for advanced chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ALL). Relapsed disease is the major cause of trea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cccbf29746cd75bc97b5bce750a1facc
https://doi.org/10.1002/cncr.29141
https://doi.org/10.1002/cncr.29141
Autor:
Maya Koren-Michowitz, Noga Shem-Tov, Arnon Nagler, Abraham Avigdor, Ronit Yerushalmi, Hannah Maayan, Avichai Shimoni, Yulia Volchek, Arie Apel
Publikováno v:
Annals of Hematology. 94:375-378
Acute myeloid leukemia (AML) relapse is often associated with a poor outcome, especially after allogeneic stem cell transplantation (Allo-SCT). In patients relapsing early after SCT treatment, options are further limited by the fear for increased tox
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6c5b0c07d24b9a6272fc7e06724184d
https://doi.org/10.1007/s00277-014-2229-3
https://doi.org/10.1007/s00277-014-2229-3
Autor:
Maya Koren-Michowitz, Avichai Shimoni, Arnon Nagler, Israel Gavish, Elizabeth Naparstek, Itai Levi, Yulia Volchek, Jacob M. Rowe
Publikováno v:
Hematological Oncology. 30:200-205
Imatinib has been accepted as frontline treatment for patients with chronic myeloid leukaemia (CML), and patients generally receive doses ranging from 400 to 800 mg/day. Previous studies have demonstrated that maintaining imatinib plasma levels (IMPL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::26f333e77c7f8cb10bbb1dea28ff4bd5
https://doi.org/10.1002/hon.2005
https://doi.org/10.1002/hon.2005